Ebola vaccine developer Tekmira's net loss widens during second quarter
The Canadian Press
Published Wednesday, August 13, 2014 6:49PM EDT
VANCOUVER -- Tekmira Pharmaceuticals Corp. (TSX:TKM) says it's in talks with governments and non-governmental organizations in various countries about the potential use of its experimental Ebola drug in infected patients.
Given the severity of the outbreak in West Africa, the Vancouver-based company says it's "carefully evaluating options" for using its unapproved TKM-Ebola drug, but it can't assure an appropriate framework will be found.
Last week, the U.S. Food and Drug Administration relaxed a clinical hold on testing of TKM Ebola, potentially enabling its use in individuals stricken with the deadly virus.
Ebola has killed more than 1,000 people in West Africa since March.
Tekmira says its net loss in the second quarter was $6.1 million, or 28 cents per share, widening from $3 million, or 21 cents per share, in the same period a year earlier.
Revenue dropped to $1.8 million from $2.8 million in the same 2013 quarter.
Please read our guidelines before commenting on stories.